We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Federal Trade Commission is backing Mylan in its request for a rehearing before a panel of appellate court judges on the dismissal of the company’s antitrust case against Warner Chilcott and Mayne Pharmaceuticals. Read More
The FDA and HHS have not responded to a senator’s demand to clarify their enforcement stance on state right-to-try laws that expand terminal patients’ access to unapproved drug therapies, more than 30 days after a hearing on the issue. Read More
Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) are pressing Ariad Pharmaceuticals for answers about why the price of a cancer drug it produces has increased more than $80,000 for a year of treatment. Read More
The National Academy for State Health Policy is proposing 10 measures to reduce drug spending, which include greater transparency on pricing and better enforcement of antitrust laws. Read More
Pfizer says it plans to begin sales of a biosimilar version of Remicade in late November, despite Janssen’s appeal of a ruling that invalidated its patent covering the arthritis therapy. Read More
Switzerland’s Novartis is shuttering several of its research operations in Switzerland and China, eliminating 175 jobs, in an effort to centralize control of its drug discovery programs and curb costs. Read More